Chemoinformaics analysis of 4,4,6-TRIMETHYLCYCLOHEX-2-EN-1-ONE
| Molecular Weight | 138.21 | nRot | 0 |
| Heavy Atom Molecular Weight | 124.098 | nRig | 7 |
| Exact Molecular Weight | 138.104 | nRing | 1 |
| Solubility: LogS | -2.528 | nHRing | 0 |
| Solubility: LogP | 2.574 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 1 |
| Atoms Count | 24 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 10 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 14 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 9 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 25.1671 |
| nHD | 0 | BPOL | 14.9129 |
| QED | 0.501 |
| Synth | 3.501 |
| Natural Product Likeliness | 2.529 |
| NR-PPAR-gamma | 0.006 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.013 |
| Pgp-sub | 0 |
| HIA | 0.006 |
| CACO-2 | -4.417 |
| MDCK | 0.0000356 |
| BBB | 0.908 |
| PPB | 0.810107 |
| VDSS | 1.3 |
| FU | 0.250861 |
| CYP1A2-inh | 0.242 |
| CYP1A2-sub | 0.595 |
| CYP2c19-inh | 0.226 |
| CYP2c19-sub | 0.877 |
| CYP2c9-inh | 0.05 |
| CYP2c9-sub | 0.636 |
| CYP2d6-inh | 0.241 |
| CYP2d6-sub | 0.555 |
| CYP3a4-inh | 0.085 |
| CYP3a4-sub | 0.332 |
| CL | 6.161 |
| T12 | 0.512 |
| hERG | 0.026 |
| Ames | 0.081 |
| ROA | 0.789 |
| SkinSen | 0.762 |
| Carcinogencity | 0.759 |
| EI | 0.982 |
| Respiratory | 0.941 |
| NR-Aromatase | 0.011 |
| Antiviral | No |
| Prediction | 0.953797 |